Toggle menu

HEAD Study

Start date:
1st August 2019
End date:
31st August 2019
Co-ordinated by:
Julia Grahamslaw

Prospective multicentre observational study conducted over one calendar month in 2019, with a planned sample size of 1000 over 5 sites. The aim of the study was to describe the epidemiology of non-trauma related headache in adults presenting to emergency departments including investigations, treatments and outcome.

This includes adult patients presenting to the ED with non-trauma-related headache as their primary complaint.

This was a study working in collaboration with the Trainee Emergency Medicine Research Network (TERN) to understand the international epidemiology of patients presenting to the ED with a headache.

 

Research Team

Julia Grahamslaw

Lead Research Nurse

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Sian Dalgleish

Senior Research Nurse

More EMERGE Trials

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Read more

NOVEL Study

Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions

Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.

Read more

INFERENCE

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial